Loading clinical trials...
Loading clinical trials...
Ketones, Muscle Metabolism, and SGLT2 Inhibitors
Conditions
Interventions
Empagliflozin 25 MG Oral Tablet
Placebo
+1 more
Locations
1
United States
Texas Diabetes Institute - University Health System
San Antonio, Texas, United States
Start Date
January 25, 2024
Primary Completion Date
November 1, 2026
Completion Date
March 1, 2027
Last Updated
February 5, 2026
NCT07057466
NCT05909046
NCT06859970
NCT06479876
NCT06964464
NCT05603273
Lead Sponsor
The University of Texas Health Science Center at San Antonio
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions